Erratum: Department of Error (The Lancet (2019) 393(10188) (2303–2311), (S0140673619304192), (10.1016/S0140-6736(19)30419-2));Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

The Lancet

Volumn 393, Issue 10188, 2019, Pages 2303-2311

  Smolen, Josef S ^a   Pangan, Aileen L ^b   Emery, Paul ^c   Rigby, William ^d   Tanaka, Yoshiya ^e   Vargas, Juan Ignacio ^f   Zhang, Ying ^b   Damjanov, Nemanja ^g   Friedman, Alan ^b   Othman, Ahmed A ^b   Camp, Heidi S ^b   Cohen, Stanley ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d DARTMOUTH COLLEGE   (United States)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f Quantum Research   (Chile)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h METROPLEX CLINICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; UPADACITINIB; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS; JANUS KINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCREENING; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; YOUNG ADULT; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; JANUS KINASE INHIBITORS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 85066764280     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31474-6     Document Type: Erratum

References (29)

1. Smolen, JS, Landewe, R, Bijlsma, J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76 (2017), 960–977.
2. Singh, JA, Saag, KG, Bridges, SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68 (2016), 1–26.
3. Emery, P, Breedveld, FC, Hall, S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008), 375–382.
4. van der Kooij, SM, de Vries-Bouwstra, JK, Goekoop-Ruiterman, YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66 (2007), 1356–1362.
5. Schnabel, A, Herlyn, K, Burchardi, C, Reinhold-Keller, E, Gross, WL, Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int 15 (1996), 195–200.
6. Visser, K, van der Heijde, D, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68 (2009), 1094–1099.
7. Curtis, JR, Xie, F, Mackey, D, Gerber, N, et al. Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord, 17, 2016, 405.
8. Nikiphorou, E, Negoescu, A, Fitzpatrick, JD, et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 33 (2014), 609–614.
9. Emery, P, Sebba, A, Huizinga, TW, Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1897–1904.
10. Flipo, RM, Maillefert, JF, Chazerain, P, et al. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open, 3, 2017, e000340.
11. Walker, JG, Smith, MD, The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32 (2005), 1650–1653.
12. Rawlings, JS, Rosler, KM, Harrison, DA, The JAK/STAT signaling pathway. J Cell Sci 117 (2004), 1281–1283.
13. Burmester, GR, Kremer, JM, Van den Bosch, F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391 (2018), 2503–2512.
14. Genovese, MC, Fleischmann, R, Combe, B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391 (2018), 2513–2524.
15. Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
16. Felson, DT, Anderson, JJ, Boers, M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995), 727–735.
17. Prevoo, ML, van 't Hof, MA, Kuper, HH, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995), 44–48.
18. Bykerk, VP, Massarotti, EM, The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology 51:suppl 6 (2012), vi16–vi20.
19. Woodworth, T, Furst, DE, Alten, R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 34 (2007), 1401–1414.
20. NCI. Common Terminology Criteria for Adverse Events v4.0. May 29, 2009, NCI, NIH, DHHS NIH publication # 09-7473. 2009.
21. Listing, J, Strangfeld, A, Rau, R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low—results from RABBIT, the German biologics register. Arthritis Res Ther, 8, 2006, R66.
22. Soliman, MM, Ashcroft, DM, Watson, KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70 (2011), 583–589.
23. Zink, A, Listing, J, Kary, S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64 (2005), 1274–1279.
24. Kavanaugh, A, Kremer, J, Ponce, L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76 (2017), 1009–1019.
25. Fleischmann, R, Kremer, J, Cush, J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
26. Smolen, JS, Aletaha, D, McInnes, IB, Rheumatoid arthritis. Lancet 388 (2016), 2023–2038.
27. van Vollenhoven R, Takeuchi T, Pangan AL, et al. A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis (abstract). ACR/ARHP (2018) American College of Rheumatology/ARHP—2018 Annual Scientific Meeting; Chicago, Illinois, USA: Arthritis and Rheumatology; 2018.
28. Genovese, MC, Kremer, J, Zamani, O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
29. Charles-Schoeman, C, Gonzalez-Gay, MA, Kaplan, I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum 46 (2016), 71–80.